Comparative Pharmacology
Head-to-head clinical analysis: LODINE versus MECLOFENAMATE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LODINE versus MECLOFENAMATE SODIUM.
LODINE vs MECLOFENAMATE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibition of prostaglandin synthesis via cyclooxygenase (COX) inhibition, with selectivity for COX-2 over COX-1.
Meclofenamate sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
200 to 400 mg orally every 6 to 8 hours as needed; maximum daily dose 1200 mg.
50 mg or 100 mg orally three times daily; maximum 400 mg/day.
None Documented
None Documented
Terminal elimination half-life approximately 7.5 hours; in elderly or renal impairment, half-life may be prolonged up to 10 hours, requiring dose adjustment
2-4 hours (terminal half-life; may be prolonged in hepatic impairment or elderly)
Primarily renal (60% as metabolites, <1% unchanged); biliary/fecal (30-35%)
Renal (60-70% as metabolites and conjugates), biliary/fecal (20-30%)
Category C
Category C
NSAID
NSAID